Home › Trials › NCT05603351
Clinical trial No longer in our active list Interventional Ages 50 to 69 Men only

Screening for prostate cancer using a new MRI method

Official title: ProstaPilot: Prostate Cancer Screening Using MRI With an Abbreviated Protocol

Run by Masaryk Memorial Cancer Institute · NCT05603351 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing a new MRI method to see if it can better screen for serious prostate cancer in men aged 50-69 while reducing unnecessary tests and procedures.

Quick facts

Study typeInterventional
Ages50 Years to 69 Years
SexMen only
Enrollment300 (estimated)
SponsorMasaryk Memorial Cancer Institute
Academic / other
Locations1 site (Brno, Czech Republic)
Trial IDNCT05603351 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are men aged 50-69 with no prior prostate cancer diagnosis or recent PSA tests.

Probably not a fit

Patients with known prostate cancer, contraindications to MRI, or recent prostate biopsies will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of a biparametric MRI protocol for screening clinically significant prostate cancer in men aged 50-69. It involves a series of tests including serum PSA levels, MRI scans, and biopsies if necessary, all conducted under strict blinding to ensure unbiased results. The goal is to reduce the detection of non-significant cancers and improve the accuracy of prostate cancer screening. The study aims to establish a more effective screening method that minimizes unnecessary procedures and healthcare burdens.

Why it matters

Potential benefit: If successful, this approach could lead to more accurate prostate cancer screenings, reducing unnecessary treatments and improving patient outcomes.

How similar studies have gone: Other studies have shown promise in using MRI for prostate cancer detection, but this specific biparametric approach is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age 50-69 years
* Life expectancy over 10 years
* Ability to undergo all planned procedures (without contraindications to MRI or biopsy)
* No known prostate cancer or prostate biopsy in the past (interventions for BPH are not a restriction)
* No PSA test or prostate MRI in the past 2 years.
* No signs of prostatitis or urinary tract infection in the past 6 months.
* Signed informed consent.

Exclusion Criteria:

* Contraindications to MRI
* Hip replacement
* Known BRCA1/BRCA2 mutation

Where it's running

  • Masaryk Memorial Cancer Institute
    Brno, Czech Republic, Czechia     Recruiting

Study contacts

  • Principal investigator: Michal Staník, MD,PhD. — Masaryk Memorial Cancer Institute
  • Study coordinator: Michal Standara, MD
  • Email: standara@mou.cz
  • Phone: 00420 543 136 008

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostate Cancer 1464Masaryk Memorial Cancer Institute 10
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.